PWAM
RVNC

Park West Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Park West Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-319,015
Closed -$3.66M – 51
2023
Q3 		$3.66M Buy
+319,015
New +$6.13M 0.34% 34

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Park West Asset Management's RVNC Position: Q4 2023 in Review

Park West Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 319,015 shares — an estimated $3.66M sold.

Park West Asset Management first reported a position in RVNC in Q3 2023 and held it in 1 quarter. The position peaked at $3.66M in Q3 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Park West Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Park West Asset Management sold 319,015 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $3.66M.
  • Park West Asset Management first reported a position in Revance Therapeutics, Inc. in Q3 2023 and held it in 1 quarter.
  • Park West Asset Management's Revance Therapeutics, Inc. position peaked at $3.66M in Q3 2023.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Park West Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.